[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.124.106. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Citations 0
Correction
June 21, 2006

Reported Outcomes in Major Cardiovascular Clinical Trials Funded by For-Profit and Not-for-Profit Organizations: 2000-2005—Correction

JAMA. 2006;295(23):2726. doi:10.1001/jama.295.23.2726-b

Incomplete Financial Disclosure: In the Original Contribution entitled “Reported Outcomes in Major Cardiovascular Clinical Trials Funded by For-Profit and Not-for-Profit Organizations: 2000-2005” published in the May 17, 2006, issue of JAMA (2006;295:2270-2274), financial disclosures were omitted. Dr Ridker reports that he has received research funding and research support from the National Heart, Lung, and Blood Institute, the Doris Duke Charitable Foundation, the Leducq Foundation, the Donald W. Reynolds Foundation, the American Heart Association, the James and Polly Annenberg La Vea Charitable Trusts, AstraZeneca, Bayer, Bristol-Myers Squibb, Dade-Behring, Novartis, Pharmacia, Roche, Sanofi/Aventis, and Variagenics. Dr Ridker reports being listed as a coinventor on patents held by the Brigham and Women's Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease and has served as a consultant to Schering-Plough, Sanofi/Aventis, AstraZeneca, Isis Pharmaceuticals, Dade-Behring, and Interleukin Genetics. Mr Torres reported no financial disclosures.

×